Jay Peredo
14.9K posts

Jay Peredo
@jayperedox
building the adherence layer for peptides + glp-1’s at @peptracker | prev many places, many things (2x exits)



Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. on.wsj.com/4uSOB7Y



Day 3 Update on Tirz + BPC-157 > Nausea has subsided > Woke up again after 6 hours of sleep > Ate ~1200 calories, mostly protein slop. Hard to eat more > Scared I'm going to lose all my muscle mass > Getting Dexa scan today to make sure Any tips on improving sleep?




Peptide Sciences, arguably one of the largest research peptide vendors, just announced they’re shutting down. That’s a pretty big deal considering how long they’ve been around. It also likely won’t be the last. As compounding pharmacies gain clearer pathways to prescribe peptides, the old “research peptide” vendor model becomes harder to sustain. A few things worth knowing: - This doesn’t mean peptides are going away - Some gray-market vendors will likely disappear - New ones will also show up quickly When a big vendor disappears, the market doesn’t disappear. It fragments.







Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…

Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…











